It was a black, black Wednesday for Ampio Pharmaceuticals (NYSE: AMPE) as its stock slumped to a value of just $0.61.
That represents a 79% decline in a day and in after-hours trading the value slipped by a further 26%, hinting at a tough day to come on Thursday too.
The reason for the investor desertion was that the US Food and Drug Administration (FDA) ruled that a further study was needed for the company’s treatment of osteoarthritis of the knee, to support a marketing application.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze